A new medication that’s injected daily at mealtime has received FDA approval to help improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Lixisenatide, marketed as Adlyxin, is a glucagon-like peptide-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying. It will be available in a disposable, prefilled pen (http://bit.ly/2aP9yxj).
Voelker R. Injectable Diabetes Drug Approved . JAMA. 2016;316(11):1142. doi:10.1001/jama.2016.12431